SGLT2 inhibitors, RAAS inhibitors, nsMRAs, & GLP-1 receptor Agonists

Author(s):

Rajiv Agarwal, MD,Mark A. Meeker, DO, FACP, CPE

Key Takeaways

SGLT2 inhibitors reduce glucose reabsorption, providing renal and cardiovascular benefits in CKD management for type 2 diabetes patients.
RAAS inhibitors target the renin-angiotensin-aldosterone system, reducing blood pressure and proteinuria, slowing CKD progression.
GLP-1 receptor agonists enhance insulin secretion and offer cardiovascular protection, contributing to CKD management.
Hyperkalemia management includes dietary potassium restriction, potassium binders, and medication adjustments to maintain treatment efficacy.

Panelists discuss how SGLT2 inhibitors, RAAS inhibitors, and GLP-1 receptor agonists differ in their treatment of chronic kidney disease (CKD) in patients with type 2 diabetes, along with strategies for managing hyperkalemia in patients to help them resume their treatment course.

How do SGLT2 inhibitors, RAAS inhibitors, and GLP-1 receptor agonists differ in their treatment of CKD in patients with type 2 diabetes?
Discuss your approach for patients who experience hyperkalemia during treatment. What strategies do you use to help them get back on their treatment course?